Table 8. Breakdown of anticipated diagnostics launches by archetype (assay development versus simple technical platform development) and disease parameters, percentage change from baseline, estimated cost ($, millions), estimated number of product launches.
| Disease | Diagnostic
launches: assay development |
Diagnostic launches: simple
technical platform development |
Total
diagnostics |
|---|---|---|---|
| Tuberculosis | 16 | 11 | 27 |
| Malaria | 7 | 7 | 14 |
| HIV/AIDS | 7 | 6 | 13 |
| Hepatitis C | 6 | 1 | 7 |
| Leishmaniasis | 3 | 0 | 3 |
| Buruli ulcer | 2 | 0 | 2 |
| Chagas disease | 1 | 1 | 2 |
| Dengue | 1 | 0 | 1 |
| HAT (sleeping sickness) | 1 | 0 | 1 |
| Leptospirosis | 1 | 0 | 1 |
| Lymphatic filariasis | 1 | 0 | 1 |
| Schistosomiasis | 1 | 0 | 1 |
| TOTAL | 47 | 26 | 73 |